Clinical Medicine Insights: Oncology
Clinical Medicine Insights: Oncology is a peer-reviewed open access journal that focuses on all aspects of cancer research and treatment, in addition to related genetic, pathophysiological, and epidemiological topics. Please see the aims and scope tab for further information.
This journal is a member of the Committee on Publication Ethics (COPE).
- Gold open access journal – all articles are made freely available online immediately upon publication.
- Rigorous peer review.
- Listed in PubMed and indexed in Science Citation Index Expanded (SCIE) and Scopus.
Submission information
Submit your manuscript today at https://mc.manuscriptcentral.com/onc.
Please see the Submission Guidelines tab for more information on how to submit your article to the journal.
Open access information
The article processing charge (APC) for this journal is currently 3000 USD.
The APC is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Please see further details here.
Contact
Please direct any queries to Dr. Amy Goundry at cmi.oncology@sagepub.co.uk.
Clinical Medicine Insights: Oncology is an international, peer-reviewed, open access journal which publishes articles on all aspects of cancer research and treatment. Of particular but not exclusive interest are molecular biology; genetics; pathophysiology; epidemiology; clinical interventions; controlled trials; diagnosis and treatment of patients with cancer; therapeutics, pharmacology and drug delivery; and techniques of cancer surgery.
The journal welcomes a wide range of article types, including original research, review, systematic review, meta-analysis, study protocols, and Letters to the Editor. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. All articles are listed on PubMed and are freely available via PubMed Central.
Our goal is to publish sound science. This means we look for research that adheres to ethical standards, uses robust methodologies that are transparent and reproducible, and uses appropriate statistical analyses to ensure clear, credible, and trustworthy results. We care more about the quality and reliability of the contribution an article makes than we do the size of that contribution. Clinical Medicine Insights: Oncology evaluates manuscripts based on how the research was conducted and reported.
| Lingling Tian, PhD | SAGE Publishing, Shanghai, China |
| George Vlachogiannis, PhD | SAGE Publishing, London, UK |
| Applonia Rose, PhD | SAGE Publishing, London, UK |
| William Cho | Kowloon, Hong Kong, China |
| Jeanny B. Aragon-Ching | Virginia Commonwealth University; Inova Schar Cancer Institute, USA |
| Giuseppe Badalamenti | University of Palermo, Italy |
| Giuseppe Luigi Banna | Portsmouth Hospitals University NHS Trust, UK |
| Matthew Basel | Kansas State University, USA |
| Federico Cappuzzo | National Cancer Institute IRCCS Regina Elena, Italy |
| Quan Cheng | Central South University, China |
| Yoh Dobashi | International University of Health and Welfare, Tochigi, Japan |
| Federico Ferrari | University of Brescia, Italy |
| Mazdak G. Hakemi | Regenerative and Restorative Medicine Research Center (REMER), Research Institute for Health Sciences and Technologies (SABITA), Istanbul Medipol University, Istanbul, Turkey |
| Cheng-Maw Ho | National Taiwan University Hospital and College of Medicine, Taiwan |
| Md. Wasim Khan | Barbara Ann Karmanos Cancer Institute, Wayne State University, USA |
| Qian Liu | National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China |
| Xuelei Ma | West China Hospital, Sichuan University, China |
| Rikesh Makanji, MD | Moffitt Cancer Centre, USA |
| Makiko Ono | Cancer Institute Hospital, Japan |
| Stamatios Petousis | Aristotle University of Thessaloniki, Greece |
| Giandomenico Roviello | University of Florence, Florence, Italy |
| Tevfik Tolga Sahin | Inonu University liver Transplant Institute, Turkey |
| Dong Tang | Northern Jiangsu People’s Hospital, Yangzhou University, China |
| Tomoyuki Abe | Onomichi General Hospital, Japan |
| Clement A. Adebamowo | University of Maryland School of Medicine, USA |
| Samuel E. Adunyah | Meharry Medical College, USA |
| Sung G. Ahn | Yonsei University College of Medicine, Seoul, Republic of Korea |
| Abass Alavi | Perelman School of Medicine, University of Pennsylvania, USA |
| Claudio Casella | University of Brescia, Italy |
| Sakti Chakrabarti | Medical College of Wisconsin, USA |
| Kathleen Cooney | University of Utah School of Medicine, USA |
| Gianluca Costa | Campus Bio-Medico University of Rome, Italy |
| Xiaolan Fang | New York Genome Center, USA |
| Elana Farace | Penn State College of Medicine, USA |
| Pier Francesco Ferrucci | European Institute of Oncology, Italy |
| Thomas M. Habermann | Mayo Clinic, USA |
| Krishnamachar Harish | M. S. Ramaiah Medical College, India |
| Bangshun He | Nanjing First Hospital, Nanjing Medical University, China |
| Stephen Hiscox | Cardiff University, UK |
| Jennifer J Hu | University of Miami Miller School of Medicine, Miami, Florida, USA |
| Nagraj G Huilgol | Nanavati Hospital , India |
| David H Ilson | Memorial Sloan-Kettering Cancer Center, New York, NY, USA |
| Alshad S Lalani | Puma Biotechnology, USA |
| Mina Makary | The Ohio State University Medical Center, USA |
| Tarun K. Mandal | Xavier University of Louisiana, USA |
| Vladimir Neychev | University of Central Florida, USA |
| Kjell Öberg | Uppsala University, Sweden |
| Daniele Santini | Università Campus Bio-Medico, Italy |
| Miguel A. Sanz | University of Valencia; University Hospitla La Fe, Valencia, Spain |
| Preet Paul Singh | Springfield Clinic, USA |
| Frank A. Sinicrope | Mayo Clinic, USA |
| Alexander Stojadinovic | California Oncology Research Institute, USA |
| Nishant Tageja MD | Wheeling Hospital, USA |
| Michael A. Tainsky | Wayne State University School of Medicine, Detroit, Michigan, USA |
| Carlos Telleria | McGill University, Canada |
| Celalettin Ustun | University of Minnesota, USA |
| Bruno Vincenzi | University Campus Bio-Medico, Rome, Italy |
| Jan Walewski | Maria Sklodowska-Curie National Research Institute of Oncology, Poland |
| M. Wasif Saif | Northwell Health Cancer Institute, Lake Success, NY, USA |
| John Woolley | University of Liverpool, UK |
| Gutian Xiao | University of Pittsburgh, USA |
| Benny Chung-Ying Zee | The Chinese University of Hong Kong, Hong Kong SAR, China |
| Bin-Yan Zhong | Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM),Chinese Academy of Sciences, China |
| Ayushi Agarwal, MD, FICO, FLVPEI | Ophthalmic Plastic Surgery Service, Nandadeep Eye Hospital and PG Teaching Institute, Kolhapur, Maharashtra, India |
| Beena Ahsan, MD, FCAP | Henry Ford Health, Detroit, MI, USA |
| Akram Al-Ibraheem, MD, JBNM, DCBNC, FEBNM, FANMB, FRCP, FRCPE | Nuclear Medicine Department, King Hussein Cancer Center (KHCC), Jordan |
| Abdelrahman M. Attia, MD | Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA |
| Trinanjan Basu, MD, PDCR, F-ESCO, CAS-Pr | HCG Cancer Centre, Mumbai, Maharashtra, India |
| Güntug Batihan, MD | Department of Thoracic Surgery, Çanakkale Onsekiz Mart University, Çanakkale, Turkey |
| Liliana Belgioia, MD | Department of Radiation Oncology, IRCCS Ospedale Policlinico San Martino, University of Genoa, Genoa, Italy |
| Maria Rita Bianco, MD | Magna Graecia University of Catanzaro, Italy |
| Sinem Bireller, PhD | Acibadem Mehmet Ali Aydinlar University, Istanbul, Türkiye |
| Joan J. Castellano, PhD | Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA |
| Yizhen Chen, PhD | Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian, China |
| Surya Chitra, PhD | University of Delaware, USA |
| Wei Chong | Shandong Provincial Hospital Affiliated to Shandong First Medical University |
| Alfredo V. Chua, Jr., MD, MCM | Department of Cancer Prevention & Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA |
| Andrea Cimini, MD | Nuclear Medicine Unit,San Salvatore Hospital, L'Aquila, Italy |
| Alfredo Clemente, MD, PhD | Department of Life Sciences, Health and Health Professions Link Campus University, Rome, Italy |
| Amsalu Defersha, B.Pharm, MSc, M.Pharm, PhD | Department of Pharmaceutics and Pharmacy Practice, United States International University-Africa, Nairobi, Kenya |
| Emmanuel Kwateng Drokow, PhD | Hunan Provincial Key Laboratory of Clinical Epidemiology, Central South University, China |
| Baojun Duan | Shaanxi provincial people’s hospital, Xi’an medical university, China |
| Enes Erul, MD | Department of Medical Oncology, Ankara University, Ankara, Turkey |
| Gianluca Ferini, MD | REM radioterapia srl, Viagrande, Italy |
| VITTORIO GEBBIA, MD, PHD | DEPARTMENT OF MEDICINE AND SURGERY, KORE UNIVERSITY OF ENNA, ENNA, ITALY |
| Gabriella Gentile, MD | Sapienza University of Rome, Rome, Italy |
| Silvia Gigli, MD, PhD | Sandro Pertini Hospital, Via dei Monti Tiburtini, Rome, Italy |
| Zhenyu Gong, MD, PhD | Department of Neurosurgery/Neuro-Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China |
| Xiangyong Hao, MD, PhD | Gansu Provincial Hospital, China |
| Yongzhu He, MD, PhD | Shenzhen People’s Hospital, Shenzhen, Guangdong, China |
| Tieying Hou, PhD | Indiana University, USA |
| Giuseppe Iati’, MD | University of Messina, Department of Experimental and Clinical Medicine (DIMED), Messina, Italy |
| Simon Imakwu Okekpa | David Umahi Federal University of Health Sciences, Uburu, Ebonyi State, Nigeria?, Africa |
| Farhadul Islam, PhD, M Phil, MSc, Bsc | Dept. of Biochemistry and Molecular Biology, University of Rajshahi, Bangladesh |
| Munira Jahan, MD | Bangladesh Medical University, Dhaka, Bangladesh |
| Ivana Jochmanová, MUDr, Mgr, PhD | Pavol Jozef Šafárik University in Košice, Košice, Slovakia |
| Esin Aysel Kandemir | Carl von Ossietzky University of Oldenburg, Wiefelstede Germany |
| Adyb-Adrian Khal, MD, PhD | Department of Orthopaedics, Pelican Medicover Hospital of Oradea, Romania |
| Bilon Khambu, MS, PhD | Tulane University School of Medicine, Louisiana |
| Nikolaos Kostakopoulos, MD, PhD, FEBU | Honorary Associate University of Aberdeen, Consultant Metropolitan General Hospital Athens, Greece |
| Ibrahim Kulac, MD | Department of Pathology, Koc University School of Medicine, Istanbul, Turkiye |
| Rahul Kumar, PhD | Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA |
| Krishna Kumar Govindarajan, MCh, FEBPS, FACS, FIAGES, FAIS, FIAPS, FSPU, FCLS | Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India |
| Sarita Kumari, MD, MCh | Max Institute of Cancer Care, Max Superspecialty Hospital, Dwarka, New Delhi, India |
| Zhijun Li, MD | School of Pharmacy (Institute of Pharmaceutical Research), Shandong First Medical University & Shandong Academy of Medical Sciences, China |
| Yong Liu, MD | Hubei Cancer Hospital, Hubei Province, China |
| Lianxiang Luo | Guangdong Medical University, China |
| Xiao Lushan, PhD | Southern Medical University, China |
| Abhinava K. Mishra, PhD | Molecular Cellular and Developmental Biology Department, University of California, Santa Barbara, CA, USA |
| Neelam Mukherjee, PhD | UT Health San Antonio, San Antonio, TX, USA |
| Yongdong Niu, MD, PhD | Department of Pharmacology, Shantou University Medical College, Guangdong, China |
| Nabil Elhadi Omar, BSc Pharm, BCOP, PharmD, PGcert.(PGx), PhD | National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar |
| Coral Omene, MD, PhD | Robert Wood Johnson Medical School, Rutgers Cancer Institute, New Brunswick, NJ, USA |
| Armando Orlandi, PhD | Comprehensive Cancer Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy |
| See-Hyoung Park, PhD | Hongik University, Republic of Korea |
| Asim Pervaiz, PhD | University of Health Sciences, Lahore, Pakistan |
| Rao h. Prabhala, PhD | Harvard Medical School, USA |
| Zhiyuan Qin, PhD | University of Pennsylvania, USA |
| Kakil Ibrahim Rasul, CABM, FRCP, ESMO | National Center for Cancer Care and Research(NCCCR) Medical Oncology Department, Doha, Qatar |
| Belson Rugwizangoga, MD, MMed, PhD | Department of Pathology, University Teaching Hospital of Kigali, University of Rwanda, Rwanda |
| Marco Ruiz Andia, MD, MPH, MSc, MBA, CPE | Miami Cancer Institute, Florida |
| Anita Sejben MD, PhD | Department of Pathology, University of Szeged, Szeged, Hungary |
| Chuan Shao, MMed | Chongqing General Hospital, Chongqing University, China |
| Lipei Shao, PhD | Center for Cellular Engineering, National Institutes of Health, U.S. |
| Ahmed Shehta, MD, FACS | Liver Transplantation Unit, Gastrointestinal Surgery Center, Department of Surgery, College of Medicine, Mansoura University, Egypt |
| Jie Shen, PhD | University of Virginia, USA |
| Mitsugi Shimoda, MD, PhD | Department of Gastroenterological Surgery, Tokyo Medical University, Ibaraki Medical Center, Japan |
| Ritis Kumar Shyanti, PhD | Cancer Biology Research and Training Program (CBRT) at Alabama State University (ALASU), USA |
| Vivek Singh, PhD | Thoracic Surgery Branch, National Cancer Institute, NIH, Bethesda, MD, USA |
| Vladyslav Sukhin, MD, PhD, MSc | Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine, Kharkiv, Ukraine |
| Marin Valeriu Surlin, MD, PhD, MSc | University of Medicine and Pharmacy of Craiova, Romania |
| Osman Sütcüoglu, MD | Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey |
| Hirotaka Suto, MD, PhD | Hyogo Cancer Center, Japan |
| Yi Jer Tan, PhD | Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, NYU Langone Health, New York, NY, USA |
| Zheqiong Tan, MD, PhD | Tongji Medical College, Huanzhong University of Science and Technology, China |
| Ozgur Tanriverdi, MD, MSc, PhD | Department of Medical Oncology, Mugla Sitki Kocman University, Mugla, Türkiye |
| Mustafa Zafer Temiz, MD, PhD, FEBU | Department of Urology, University of Health Sciences, Bagcilar Training and Research Hospital, Istanbul, Turkiye |
| Francesco Tiralongo, MD | University Hospital Policlinico “G. Rodolico-San Marco”, University of Catania, Catania, Italy |
| Silvia Vanni | IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola, Italy |
| Federico Venturi, MD | Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy |
| Vladimir Jurisic, PhD, MD | University of Kragujevac, Serbia |
| Ruohao Wu | Sun Yat-sen Memorial Hospital, Guangzhou, China |
| Shao-Jun Xu, MD | Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China |
| Melek Yakar, MD | Eskisehir Osmangazi University, Eskisehir, Turkey |
| Emre Yekeduz, MD | Department of Medical Oncology, Ankara University, Ankara, Turkiye |
| Yi Zeng | Fujian Cancer Hospital, USA |
| Shuaishuai Zhang, PhD | South China Normal University, China |
| Wenfeng Zhang, MD, PhD | Second Affiliated Hospital of Chongqing Medical University, China |
| Yingjie Zhang, PhD | School of Pharmaceutical Sciences, Shandong University, Ji'nan, China |
| Shutao Zheng | Clinical Medical Research Institute,The First Affiliated Hospital of Xinjiang Medical University, China |
| Xudong Zhu, MD, PhD | University of Kentucky, Lexington, USA |
Clinical Medicine Insights: Oncology Manuscript Submission Guidelines
Table of Contents:
1. Open Access
2. Article processing charge (APC)
3. What do we publish?
3.1 Aims & scope
3.2 Article types
3.3 Writing your paper
4. Editorial policies
4.1 Peer review policy
4.2 Authorship
4.3 Acknowledgements
4.4 Funding
4.5 Declaration of conflicting interests
4.6 Research ethics and patient consent
4.7 Clinical trials
4.8 Reporting guidelines
5. Publishing policies
5.1 Publication ethics
5.2 Contributor’s publishing agreement
6. Preparing your manuscript
6.1 Word processing formats
6.2 Artwork, figures and other graphics
6.3 Supplementary material
6.4 Reference style
6.5 English language editing services
7. Submitting your manuscript
7.1 How to submit your manuscript
7.2 Title, keywords and abstracts
7.3 Information required for completing your submission
7.4 ORCID
7.5 Permissions
8. On acceptance and publication
8.1 SAGE Production
8.2 Online publication
8.3 Promoting your article
9. Further information
This Journal is a member of the Committee on Publication Ethics.
This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).
Please read the guidelines below then visit the journal’s submission site https://mc.manuscriptcentral.com/onc to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.
Only manuscripts of sufficient quality that meet the aims and scope of Clinical Medicine Insights: Oncology will be reviewed.
As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.
Clinical Medicine Insights: Oncology is an open access, peer-reviewed journal. Each article accepted by peer review is made freely available online immediately upon publication, is published under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the journal are covered by the collection of article processing charges which are paid by the funder, institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to the journal.
For general information on open access at SAGE please visit the Open Access page or view our Open Access FAQs.
2. Article processing charge (APC)
If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable. This APC covers the cost of publication and ensures that your article will be freely available online in perpetuity under a Creative Commons license. The article processing charge (APC) is $1,200*.
*If the paying party is based in the European Union, to comply with European law, value added tax (VAT) must be added to the APC. Providing a VAT registration number will allow an institution to be exempt from paying this tax, except for UK institutions.
Before submitting your manuscript to Clinical Medicine Insights: Oncology, please ensure you have read the Aims & Scope.
- Original Articles. The Editors will consider preclinical, interventional and observational studies with clearly stated aims, well-reported methodology (including main outcome measures) and results, and a discussion of the results in the context of the published literature).
- Review Articles. The following types of high-quality review will be considered: (a) General reviews that provide a synthesis of an area that fits within the aims and scope of the journal; (b) Drug reviews – review articles focusing on the available evidence for the use of a particular drug or combination therapy.
- Perspective Reviews. Review-style articles that address important new areas of general interest and afford the author the opportunity to present a forward-looking perspective on the topic and/or incorporate their own experience in the field;
- Systematic Reviews. These should answer a specific research question and be reported according to the PRISMA guidelines. They should also include a PRISMA flow chart as a cited figure and a completed PRISMA checklist as a supplementary file (please see section 4.8).
- Meta-analyses. These should answer a specific research question and be reported according to the PRISMA guidelines. They should also include a PRISMA flow chart as a cited figure and a completed PRISMA checklist as a supplementary file (please see section 4.8).
- Case Reports. These structured reports should describe an unusual case and include a full review of the pertinent literature and a section on implications for clinical care.
- Study Protocols. These can be for forthcoming or ongoing research. Information on trial registration (where applicable) and ethics approval should be included in the manuscript.
- Editorials. Editorials are short articles on topics of recent interest that discuss the findings, implications, and/or outcomes of specific research or wider research on a general topic. These articles are usually commissioned by the Editor.
- Opinion. Similar to Editorials, these short articles address a topic under debate, and provide the opportunity for the author to voice their opinion on a particular study or area of research. These articles are usually commissioned by the Editor.
- Letters to the Editor. These brief pieces should be as concise as possible, usually no more than 1000 words.
The SAGE Author Gateway has some general advice and on how to get published, plus links to further resources.
3.3.1 Making your article discoverable
When writing up your paper, think about how you can make it discoverable. The title, keywords and abstract are key to ensuring readers find your article through search engines such as Google. For information and guidance on how best to title your article, write your abstract and select your keywords, have a look at this page on the Gateway: How to Help Readers Find Your Article Online
Following a preliminary triage to eliminate submissions unsuitable for Clinical Medicine Insights: Oncology all papers are sent out for review. The covering letter is important. To help the Editor in his preliminary evaluation, please indicate why you think the paper is suitable for publication. If your paper should be considered for fast-track publication, please explain why.
The journal’s policy is to have manuscripts reviewed by two expert reviewers. Clinical Medicine Insights: Oncology utilizes a single-blind peer review process in which the reviewer’s name and information is withheld from the author. Reviewers may at their own discretion opt to reveal their names to the author in their review but our standard policy practice is for their identities to remain concealed. All manuscripts are reviewed as rapidly as possible, while maintaining rigor. Reviewers make comments to the author and recommendations to the Editor-in-Chief who then makes the final decision.
The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor / Board member will have no involvement in the decision-making process.
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors. The list of authors should include all those who can legitimately claim authorship. This is all those who:
- Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
- Drafted the article or revised it critically for important intellectual content,
- Approved the version to be published,
- Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
Authors should meet the conditions of all of the points above. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services.
Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.
Clinical Medicine Insights: Oncology requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
4.5 Declaration of conflicting interests
It is the policy of Clinical Medicine Insights: Oncology to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles. Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’. For guidance on conflict of interest statements, please see the ICMJE recommendations.
4.6 Research ethics and patient consent
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants
All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The journal has adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals published by the International Association of Veterinary Editors
Clinical Medicine Insights: Oncology conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.
SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.
Clinical Medicine Insights: Oncology and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.
If material has been previously published, it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.
5.2 Contributor’s publishing agreement
Before publication SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. Clinical Medicine Insights: Oncology publishes manuscripts under Creative Commons licenses. The standard license for the journal is Creative Commons by Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit SAGE's OA licenses page Alternative license arrangements are available, for example, to meet particular funder mandates, made at the author’s request.
The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.
6.2 Artwork, figures and other graphics
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines
Figures supplied in color will appear in color online.
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. These will be subjected to peer-review alongside the article. For more information please refer to our guidelines on submitting supplementary files, which can be found within our Manuscript Submission Guidelines page.
Clinical Medicine Insights: Oncology adheres to the AMA reference style. Please review the guidelines on AMA to ensure your manuscript conforms to this reference style.
If you use EndNote to manage references, you can download the AMA output file here.
6.5 English language editing services
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.
7.1 How to submit your manuscript
Clinical Medicine Insights: Oncology is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit https://mc.manuscriptcentral.com/onc to login and submit your article online.
IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.
7.2 Title, keywords and abstracts
Please supply a title, short title, an abstract and keywords to accompany your article. The title, keywords and abstract are key to ensuring readers find your article online through online search engines such as Google. Please refer to the information and guidance on how best to title your article, write your abstract and select your keywords by visiting the SAGE Journal Author Gateway for guidelines on How to Help Readers Find Your Article Online.
7.3 Information required for completing your submission
Provide full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors. These details should be presented separately to the main text of the article to facilitate anonymous peer review.
You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).
As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a persistent digital identifier that distinguishes researchers from every other researcher and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities ensuring that their work is recognized.
We encourage all authors to add their ORCIDs to their SAGE Track accounts and include their ORCIDs as part of the submission process. If you don’t already have one you can create one here.
Authors are responsible for obtaining permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please visit our Frequently Asked Questions on the SAGE Journal Author Gateway.
8. On acceptance and publication
If your paper is accepted for publication after peer review, you will first be asked to complete the contributor’s publishing agreement. Once your manuscript files have been checked for SAGE Production, the corresponding author will be asked to pay the article processing charge (APC) via a payment link. Once the APC has been processed, your article will be prepared for publication and can appear online within an average of 30 days. Please note that no production work will occur on your paper until the APC has been received.
Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorizing the change.
One of the many benefits of publishing your research in an open access journal is the speed to publication. With no page count constraints, your article will be published online in a fully citable form with a DOI number as soon as it has completed the production process. At this time it will be completely free to view and download for all.
Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article. Find out how to maximize your article’s impact with Kudos.
Any correspondence, queries or additional requests for information on the Manuscript Submission process should be sent to the Clinical Medicine Insights: Oncology editorial office as follows:
Georgia Patey, georgia.patey@sagepub.co.uk